发布求助
文献互助 智能选刊 最新文献

Medicom Conference Report ASH 2023最新文献

筛选
英文 中文
MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML 在NPM1突变的急性髓细胞性白血病患者中，MRD状态而非FLT3-ITD联合突变与CR1-allo的获益有关
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/0eb68c68
Robert van den Heuvel
{"title":"MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML","authors":"Robert van den Heuvel","doi":"10.55788/0eb68c68","DOIUrl":"https://doi.org/10.55788/0eb68c68","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"99 1-2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139895537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ancestry-specific study into CH delivers new leads 针对 CH 的祖先研究提供了新线索
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/65fb39d0
Robert van den Heuvel
{"title":"Ancestry-specific study into CH delivers new leads","authors":"Robert van den Heuvel","doi":"10.55788/65fb39d0","DOIUrl":"https://doi.org/10.55788/65fb39d0","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"286 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139896066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia 泊马度胺可能成为首个获批治疗遗传性出血性毛细血管扩张症的疗法
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/15f5e10d
Robert van den Heuvel
{"title":"Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia","authors":"Robert van den Heuvel","doi":"10.55788/15f5e10d","DOIUrl":"https://doi.org/10.55788/15f5e10d","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"60 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139895500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants 大多数 R/R CLL 参与者在接受 Venetoclax、acalabrutinib 和 obinutuzumab 治疗后，MRD 检测不到
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/11dff369
Robert van den Heuvel
{"title":"Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants","authors":"Robert van den Heuvel","doi":"10.55788/11dff369","DOIUrl":"https://doi.org/10.55788/11dff369","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"38 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139895363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates IsKia：新型 MM 治疗方案可实现较高的 MRD 阴性率
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/0af71fa4
Robert van den Heuvel
{"title":"IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates","authors":"Robert van den Heuvel","doi":"10.55788/0af71fa4","DOIUrl":"https://doi.org/10.55788/0af71fa4","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139895369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia AUGMENT-101：revumenib治疗R/R KMT2Ar白血病取得优异疗效
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/8d122648
Robert van den Heuvel
{"title":"AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia","authors":"Robert van den Heuvel","doi":"10.55788/8d122648","DOIUrl":"https://doi.org/10.55788/8d122648","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"138 1-2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139895530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ADVANCE IV: Swift responses on efgartigimod in ITP ADVANCE IV：依非加替莫德治疗ITP的快速反应
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/a555835d
Robert van den Heuvel
{"title":"ADVANCE IV: Swift responses on efgartigimod in ITP","authors":"Robert van den Heuvel","doi":"10.55788/a555835d","DOIUrl":"https://doi.org/10.55788/a555835d","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"75 9-10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139895905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising results for olverembatinib in combination with venetoclax for Ph+ ALL olverembatinib联合venetoclax治疗Ph+ ALL取得良好效果
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/04e2f696
Robert van den Heuvel
{"title":"Promising results for olverembatinib in combination with venetoclax for Ph+ ALL","authors":"Robert van den Heuvel","doi":"10.55788/04e2f696","DOIUrl":"https://doi.org/10.55788/04e2f696","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"14 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139896049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KdD outperforms Kd in R/R MM also in participants with poor renal function 对于肾功能不佳的 R/R MM 患者，KdD 也优于 Kd
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/b1ef6b9f
Robert van den Heuvel
{"title":"KdD outperforms Kd in R/R MM also in participants with poor renal function","authors":"Robert van den Heuvel","doi":"10.55788/b1ef6b9f","DOIUrl":"https://doi.org/10.55788/b1ef6b9f","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"55 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139896060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma? 异基因干细胞移植是治疗 R/R LBCL 或 R/R T 细胞淋巴瘤的可靠选择吗？
Medicom Conference Report ASH 2023 Pub Date : 2024-02-07 DOI: 10.55788/396fc596
Robert van den Heuvel
{"title":"Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?","authors":"Robert van den Heuvel","doi":"10.55788/396fc596","DOIUrl":"https://doi.org/10.55788/396fc596","url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"281 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139896071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信